SCHEDULE: Morgan Stanley Discloses 5% Stake in Jasper Therapeutics

Morgan Stanley has disclosed a 5.0% beneficial ownership stake in Jasper Therapeutics, Inc., holding 758,453 shares of Voting Common Stock as of June 30, 2025.

Summary

• Morgan Stanley reported beneficial ownership of 758,453 shares of Jasper Therapeutics, Inc. Voting Common Stock.
• This represents a 5.0% stake in the company's class of securities.
• The event requiring this statement occurred on June 30, 2025.
• Morgan Stanley holds shared voting power over 758,123 shares and shared dispositive power over 758,453 shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: The filing indicates a significant passive investment by a major financial institution, which can be viewed as a vote of confidence, though it does not imply active engagement or strategic intent.

Positives

• Morgan Stanley, a major financial institution, has taken a 5.0% stake in Jasper Therapeutics, potentially signaling institutional confidence in the company.

Negatives

• No specific negative information is disclosed in this beneficial ownership filing.

Risks

• The filing itself does not detail specific company risks; however, a large institutional holding could lead to price volatility if the holder decides to significantly alter its position.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding Jasper Therapeutics' operations or financial performance.

Management Comments

• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.

Industry Context

This filing represents a routine disclosure of a significant passive ownership stake by a major financial institution, common across various industries for diversified investment portfolios. It indicates a financial institution's investment in a biotechnology/pharmaceutical company.

Stakeholder Impact

• Shareholders: Increased institutional ownership may provide stability or liquidity, but also carries the potential for large block sales if the institution decides to reduce its position.

Next Steps

• Continued compliance with SEC reporting requirements for beneficial ownership.

Key Dates

Recommendation

This Schedule 13G filing indicates a significant passive stake by Morgan Stanley, suggesting institutional interest in Jasper Therapeutics. While this is generally a positive signal, the filing itself does not provide financial performance data or strategic insights to warrant a 'buy' or 'sell' recommendation. Investors should 'hold' and await further operational or financial disclosures from Jasper Therapeutics to make a more informed decision.

Keywords

Jasper Therapeutics, Morgan Stanley, beneficial ownership, Schedule 13G, common stock, institutional investment, voting common stock